anti-CD20anti-CD3 bispecific antibody MBS303 - National

mbs303MBS-303: a CD20 inhibitors, CD3 stimulants Drug, Initially developed by Beijing Mabworks Biotech Co., Ltd.,MBS303 is a CD20×CD3 T-cell-engaging bispecific antibody that has a novel 2:1 (CD20:CD3) confuration to kill malnant B cells. This dose-escalation phase Ⅰ trial evaluated the safety